PATH › value
PATH · Value
Date: 2026-07-09 | Analyst: Valuation | Price at analysis: $11.83 | Mkt cap: ~$6.13B | Shares used: 520.5M (net, dual-class-adjusted)
0. Data Notes & Assumptions (read first)
- Share count: Using 520.5M net shares outstanding per the user's guidance, not Yahoo's headline 453.4M (float-only, excludes founder Class B shares). This lowers per-share figures materially vs. what Yahoo's own
bookValue/trailingEpsfields imply. - FCF discrepancy — flagged, not resolved: Yahoo's headline
freeCashflowfield shows $511.6M trailing. Reconciling OCF − capex from the quarterly statements gives $375.2M TTM. These don't tie out (gap ≈ $136M, likely a stock-based-compensation-add-back or financing-lease classification difference in Yahoo's field). Primary analysis uses the reconciled $375.2M figure; the $511.6M figure is shown only as an aggressive alternate read. This alone swings P/FCF from ~16.3x to ~12.0x — a meaningful spread, so treat any single-point FCF multiple with caution. - GAAP EPS distortion: FY2026 GAAP net income of $282.3M includes a one-time -$181.7M tax benefit (deferred tax asset valuation allowance release). Pretax income was only ~$100.6M. Normalized EPS (pretax income ÷ 527.8M diluted shares) ≈ $0.19. Headline GAAP EPS (282.3M ÷ 527.8M) ≈ $0.535 — overstated ~2.8x versus normalized earnings power. Both are shown below; only the normalized figure is treated as defensible.
- Book value: Total stockholders' equity (FY2026, ended Jan-2026) = $2,082.6M (fetched via Yahoo
balance_sheet). BVPS = 2,082.6M ÷ 520.5M = $4.00/share.
1. Graham's Intrinsic Value — √(22.5 × EPS × BVPS)
| Basis | EPS | BVPS | Result |
|---|---|---|---|
| Normalized (primary) | $0.19 | $4.00 | ≈ $4.14 |
| Headline GAAP (aggressive/not defensible) | $0.535 | $4.00 | ≈ $6.94 |
Caveat — Graham is a weak primary tool here. UiPath is asset-light: tangible book value is thin ($4.00/share) because the platform's real value (customer relationships, IP, go-to-market motion) isn't on the balance sheet — goodwill is only $125M and net PP&E just $110M against $3.18B total assets. Per analysis_notes.md, Graham should be weighted higher for value/asset-backed plays; PATH is neither. Treat $4.14 as a deep balance-sheet floor, not a realistic fair-value target — it would only be relevant in a severe distress/liquidation scenario, which is not the current setup (no funded debt, $1.31B cash).
2. Bogle's Expected Return
Dividend yield + earnings growth ± P/E change. Dividend yield = 0% (no dividend). Using revenue/FCF growth as the earnings-growth proxy (GAAP EPS history is too short/distorted to use directly):
- Revenue growth trend: 23.6% (FY24) → 9.3% (FY25) → 12.7% (FY26) → 17.3% TTM (latest quarter) — a modest re-acceleration signal worth watching, not yet a confirmed trend.
- FCF growth (reconciled): FY24 $291.7M → FY25 $305.6M → FY26 $352.2M → TTM $375.2M — steady high-single/low-double-digit growth.
- P/E context: trailing P/E 19.7x is inflated by the tax-benefit-distorted EPS; forward P/E ~13.1x (on analyst consensus forward EPS $0.91) is more informative. The stock is down from a 52-week high of $19.84 to $11.83 — the market has already compressed the multiple meaningfully on deceleration fears.
Qualitative read: If revenue/FCF growth stabilizes in the low-teens and the multiple holds roughly flat, expected annual return is plausibly high-single-digit to mid-teens (growth alone, no dividend). If growth decelerates further toward high-single-digits, or the multiple keeps compressing on "prove it" sentiment, returns could be flat to negative. This is a genuine two-sided call — no false precision offered.
3. Dividend Yield Theory / DDM — N/A
UiPath pays no dividend. Both models are not applicable and are skipped per framework.
4. FCF-Based Approach (primary valuation lens for this name)
4.1 Multiples at current price
| Metric | Reconciled FCF ($375.2M) | Headline Yahoo FCF ($511.6M) |
|---|---|---|
| FCF/share (TTM) | $0.721 | $0.983 |
| P/FCF | 16.3x | 12.0x |
| EV/FCF (EV ≈ $4.91B, net cash ~$1.22B) | 13.1x | 9.6x |
4.2 Peer-multiple fair value
Assumption: a recently-profitable, decelerating-then-reaccelerating SaaS name with a short GAAP profitability track record reasonably trades at a discount to mature slow-growth profitable SaaS peers (which run ~20-25x FCF) and well below high-growth SaaS (~25-35x+). Applying a conservative-to-moderate 12x-20x P/FCF band to reconciled FCF/share ($0.721):
- Low end (12x): $8.65
- Mid (16x): $11.54
- High end (20x): $14.42
Cross-checked via EV/FCF (12x-16x band on $375.2M FCF, + $1.224B net cash, ÷ 520.5M shares): $11.00 - $13.88 — consistent with the P/FCF range above.
(For reference only, not weighted: applying the same band to the headline $511.6M FCF figure would imply $11.80-$19.66 — flagged as likely overstated given the reconciliation gap noted in §0.)
4.3 Reverse-DCF sanity check
Simple Gordon-growth framing: Price = FCF/share ÷ (r − g). Solving for the perpetual growth rate g the market is implicitly pricing in at $11.83, using reconciled FCF/share ($0.721) across a range of discount rates:
| Discount rate (r) | Implied perpetual FCF growth (g) |
|---|---|
| 9% | ~2.9% |
| 10% | ~3.9% |
| 11% | ~4.9% |
| 12% | ~5.9% |
Assumptions stated plainly: single-stage perpetuity (no explicit high-growth phase), FCF margin held flat at ~22% of revenue, no terminal multiple re-rating. This is a sanity check, not a precision estimate.
Read: the market is currently pricing in something close to GDP-like perpetual growth (~3-6%), well below even the decelerated FY26 revenue growth rate (12.7%) and the TTM re-acceleration (17.3%). That's a low bar — if UiPath sustains even mid-to-high single-digit growth for several more years before fading to a terminal rate, today's price looks statistically cheap on a pure FCF basis. The offsetting risk is real, though: the 3-year growth trend (23.6%→9.3%→12.7%) shows deceleration has already happened once, and agentic-AI competitive dynamics could pressure the core RPA category's growth ceiling further (a Moat-analyst question, flagged here but not resolved).
5. Small/Mid-Cap Overlay (light touch — $6.1B cap, not micro-cap)
- Growth trajectory the market is digesting: revenue growth decelerated sharply (23.6%→9.3%) before partially recovering (12.7%→17.3% TTM). The multiple compression (52-week range $9.20-$19.84, more than halved off highs) suggests the market extrapolated the deceleration phase and has not yet fully credited the recent reacceleration.
- Profitability track record is thin and recent: FY2026 was UiPath's first-ever GAAP operating-profit year (3.5% margin), after three straight years of GAAP operating losses. Combined with the tax-benefit-inflated net income, the market reasonably applies a "prove it" discount versus peers with a decade-plus of consistent profitability — this shows up as PATH's reconciled P/FCF (16.3x) sitting below what a "seasoned" profitable SaaS peer would command (often 20-25x+).
- Buyback dynamic is a genuine positive: net shares outstanding have fallen ~8.6% from the FY2024 peak (569M → 520.5M) as buybacks (93-128% of FCF recently) now outpace SBC dilution — this is a tailwind to per-share value that a pure headline-multiple comparison can understate.
- Full §6 high-risk framework is not invoked — PATH has no runway/going-concern risk (net cash $1.31B, no funded debt), so this overlay stays light per the framework's own scoping rule.
6. Fair Value Range & Verdict
| Approach | Range | Weight |
|---|---|---|
| Graham (normalized) | ~$4.14 | Low — deep-value floor only, not primary for asset-light SaaS |
| Graham (headline, aggressive) | ~$6.94 | Not defensible — shown for completeness only |
| FCF/EV-multiple (reconciled FCF, primary) | $8.65 - $14.42 (mid ~$11.50) | Primary |
| Reverse-DCF sanity check | Supports current price as pricing in only ~3-6% perpetual growth — a conservative bar | Confirms FCF-multiple range isn't unreasonable |
Fair value range: ~$9.00 - $14.50, centered around ~$11.50-$12.00, driven primarily by the FCF-multiple approach (Graham serves only as a conservative balance-sheet floor, not the central estimate, given this is an asset-light platform business rather than a classic value/book-value play).
Vs. current price ($11.83): sits almost exactly at the midpoint of the fair-value range — neither statistically cheap nor expensive on this framework, though the reverse-DCF read (low single-digit perpetual growth priced in) suggests the downside case is not particularly aggressive.
A portfolio-specific passage was removed from the public build.
Valuation-only verdict: Mixed signals, leaning fair-to-modestly-cheap
Conviction is moderate, not high — two real data-quality flags temper confidence: (1) the unresolved $375.2M vs. $511.6M FCF discrepancy, which alone swings the multiple ~30%, and (2) a GAAP earnings history too short and too distorted (one-time tax benefit) to lean on directly. The FCF-multiple approach is the most defensible lens and places the stock roughly fairly valued to modestly cheap, with the reverse-DCF check suggesting the market isn't pricing in an optimistic growth scenario. This is a valuation-only read — leaving moat durability (particularly agentic-AI disruption risk to the core RPA category) and sentiment/growth-trajectory confirmation to the manager's synthesis before treating this as a high-conviction add.